ArticleInternational journal of medical sciences2017
The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43.
Article in International journal of medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Phytochemical Modulation of the Kynurenine Pathway (KYNP) and Its Emerging Mechanistic Insights into Cancer Progression: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- AttenuatedFrontiers in immunology · 2026Review
- Bacteria-based immunosuppressive tumor microenvironment reprogramming: a promising dawn in cancer therapy.Microbial cell factories · 2025Review
- Bibliometric analysis and visualization of Connexin 43 in the field of solid tumor research(2000-2024).Frontiers in immunology · 2025Article
- Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy.Cancers · 2024Review
- Arbutin overcomes tumor immune tolerance by inhibiting tumor programmed cell death-ligand 1 expression.International journal of medical sciences · 2024Article
- Review
- Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology.Pharmaceutics · 2022Review
- Streptococcal bacterial components in cancer therapy.Cancer gene therapy · 2022Review
- Highlights of Immunomodulation inBiomedicines · 2021Review
- Innovative Approaches of Engineering Tumor-Targeting Bacteria with Different Therapeutic Payloads to Fight Cancer: A Smart Strategy of Disease Management.International journal of nanomedicine · 2021Review
- Bacteria-cancer interactions: bacteria-based cancer therapy.Experimental & molecular medicine · 2019Review
- The extracts ofInternational journal of medical sciences · 2019Article
- Eicosapentaenoic acids enhance chemosensitivity through connexin 43 upregulation in murine melanoma models.International journal of medical sciences · 2019Article
- Tumour-targeting bacteria engineered to fight cancer.Nature reviews. Cancer · 2018Review
- Eicosapentaenoic acid reduces indoleamine 2,3-dioxygenase 1 expression in tumor cells.International journal of medical sciences · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upregulation of connexin 43 (Cx43) showed potential in enhancing immune surveillance that was suppressed in the tumor microenvironment. The expression of indoleamine 2, 3-dioxygenase (IDO) is one of the crucial factors contributing to tumor immune tolerance by depletion of tryptophan and IDO-mediated tryptophan metabolites. Here, we aim to investigate the role of Cx43 in IDO production in murine tumor by using Cx43 inducers. Resveratrol (trans-3, 5, 4 '-trihydroxystilbene) is a natural plant-derived polyphenol possessing positive effect against cancer. TREATMENTS: All of which could be inhibited once the expression of Cx43 was blocked. Cx43 involved in IDO regulation might be useful in developing IDO-targeted cancer immune therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.